【藥品訊息】 Trelegy Ellipta 95/55/22 吸入劑 衛教單張

氣喘或慢性阻塞性肺病 Treatment of asthma, chronic obstructive pulmonary disease
1. Asthma: Maintenance treatment of asthma in patients ≥18 years of age.
2. Chronic obstructive pulmonary disease: Maintenance treatment of chronic obstructive pulmonary disease.
Limitations of use: Not indicated for the relief of acute bronchospasm

Corticosteroid+M3 reversible inhibitor+long-acting beta-2 agonist

Fluticasone Furoate
1. time to peak: 0.5-1hr
2. Bioavailability: 15.2%
3. Vd: 661L: High protein binding(>99%)
4. Metabolism: CYP3A4
5. Half life: 24hr
Umeclidinium
1. Time to peak: 5-15mins
2. Vd: 86L; protein binding 89%
3. Metabolism: CYP2D6、P-gp substance
4. Half life: 11hr
Vilanterol 1. Time to peak: 5-15mins
2. Vd: 165L; protein binding 94%
3. Metabolism: CYP3A4、P-gp substance
4. Half life: 11hr

1. Hypersensitivity to fluticasone, umeclidinium, vilanterol, or any component of the formulation.
2. Severe hypersensitivity to milk proteins.
3. Primary treatment of status asthmaticus or other acute episodes of chronic obstructive pulmonary disease or asthma where intensive measures are required.

Animal reproduction studies have not been conducted with this combination

It is not known if sufficient quantities of fluticasone, umeclidinium, or vilanterol are absorbed systemically following inhalation to produce detectable amounts in breast milk.
The decision to breastfeed during therapy should consider the risk and benefits.

1. Central nervous system: Headache, voice disorder
2. Gastrointestinal: Diarrhea, dysgeusia, constipation, oral candidiasis, gastroenteritis
3. Genitourinary: Urinary tract infection
4. Infection: Influenza
5. Neuromuscular & skeletal: Back pain, arthralgia
6. Respiratory: Pneumonia, bronchitis, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, cough, oropharyngeal pain, paradoxical bronchospasm
7. Postmarketing: Anaphylaxis

Asthma:
One inhalation once daily (maximum dose: 1 inhalation/day)
Chronic obstructive pulmonary disease:
One inhalation once daily (maximum dose: 1 inhalation/day)

Not recommended

No dosage adjustment necessary.

1. Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling.
2. Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, systemic fluticasone exposure may be increased up to threefold in patients with hepatic impairment; use with caution and monitor closely.

1. Do not store in an environment above 30°C.
2. Please store in a dry place away from direct heat or sunlight.